Deborah has over 10 years of Pharma/Biotech industry, which reflects positions across a broad range of strategic and operational disciplines including biotherapeutics and medical devices. Prior to launching Lindy Biosciences in 2017, Deborah joined Southeast TechInventures, an innovation lab that partners with university inventors to further develop promising university technologies. Deborah began her career at Duke University in the Program on Values & Ethics in the Marketplace. She holds a PhD in Materials Science from Duke University with a focus in biomaterials.

Gary has over 20 years of experience in the pharmaceutical, CRO/CMO, and biotechnology industries leading product development operations at clinical and commercial scale. Prior to joining Lindy, he was Vice President, CMC & Quality for NightHawk Biosciences developing an immuno-oncology portfolio and he held similar roles at BioDelivery Sciences, a specialty pharmaceutical company, and at Aldagen, a clinical-stage regenerative medicine company developing cell therapies. He founded and was Managing Partner of The Perdoceo Group, LLC, a consulting firm providing CMC product development and regulatory support to the biotechnology and pharmaceutical industry. His responsibilities have included leading research and analytical development, manufacturing and quality, and developing CDMO outsourcing relationships and guiding regulatory strategies from pre-IND through to registration. He received his B.S. in Chemistry from North Carolina State University and holds CPGP Certified GMP Professional (CPGP-ASQ) and Regulatory Affairs Certification (RAPS) certifications

Omar is an entrepreneur and operator. He served as co-founder and CEO at AbSeek Biosciences and as CEO for Vulcan Biosciences leading all pre-clinical candidates. He served as COO/CFO at Phoenix FCR Biosciences where he led late preclinical and Phase I studies. He served as VP of Clinical Operations and Finance at NuSirt Biopharma where he coordinated all the preclinical through Phase II clinical trials. He has extensive experience in venture capital and served as Chief Investment Officer for Alumshares. Omar received his Ph.D. in Molecular and Cellular Pharmacology from the University of Miami and completed a postdoctoral fellowship at Duke University. He completed an MBA from the University of North Carolina Kenan-Flagler Business School.

Neil brings over 20 years’ experience in the pharmaceutical and biotech industry with a career that has spanned the continuum from bench top drug discovery to executive leadership in international business development and marketing strategies. As the Vice-President of Corporate Strategic Partnerships at Lindy, he is responsible for building their global drug formulation and delivery platform technology brand, fortifying its industry partnerships as well as navigating the company’s corporate growth strategy. Delivering an innovative technology for Patients suffering from chronic diseases.

John is responsible for managing daily research & development activities and partner relations at Lindy. His experience in the pharmaceutical industry encompasses product development in the fields of ophthalmology, inhaled, dermatology, and parenterals ranging from invention and early development through GMP manufacturing for multiple human clinical trials. Prior to joining Lindy Biosciences in 2019, John worked at Liquidia Technologies and Envisia Therapeutics. He received his PhD in Physics from the University of Massachusetts, Amherst.